Literature DB >> 6311754

Candidacidal activity of myeloperoxidase: mechanisms of inhibitory influence of soluble cell wall mannan.

C D Wright, J U Bowie, G R Gray, R D Nelson.   

Abstract

We have previously demonstrated the ability of human neutrophil myeloperoxidase to bind to mannan isolated from Candida albicans. Mannan may therefore be a primary component of the yeast cell wall which provides for binding of myeloperoxidase, a requirement potentially important for the candidacidal activity of the enzyme. In this report, we describe experiments to consider the relationship of the mannan-binding activity of myeloperoxidase to its candidacidal activity and the possibility that free mannan may inhibit myeloperoxidase-mediated candidacidal activity. We observed that binding of myeloperoxidase to the target yeasts was required for killing of C. albicans. We also observed that addition of soluble mannan significantly reduced myeloperoxidase-mediated killing of the yeasts in a dose-dependent manner by antagonizing binding of myeloperoxidase. Soluble mannan was demonstrated to have a similar dose-dependent inhibitory effect on neutrophil-mediated candidacidal activity without influencing phagocytosis of the organism. On the basis of these observations, we speculate that mannan solubilized in plasma and tissue fluid may interfere with neutrophil-mediated host defense against Candida infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311754      PMCID: PMC264526          DOI: 10.1128/iai.42.1.76-80.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Infectious complications in renal transplant recipients.

Authors:  T C Eickhoff
Journal:  Transplant Proc       Date:  1973-09       Impact factor: 1.066

2.  Immunological observations in chronic mucocutaneous candidiasis.

Authors:  L Canales; R O Middlemas; J M Louro; M A South
Journal:  Lancet       Date:  1969-09-13       Impact factor: 79.321

3.  Antifungal effects of peroxidase systems.

Authors:  R I Lehrer
Journal:  J Bacteriol       Date:  1969-08       Impact factor: 3.490

4.  Fungal infections complicating acute leukemia.

Authors:  G P Bodey
Journal:  J Chronic Dis       Date:  1966-06

5.  Disorders of candidacidal activity and other neutrophil functions in three cases of chronic candidiasis.

Authors:  F Sacchi; M A Cisternino; A Clivio; F A Ferrari; A Fortunato; L Nespoli; A Beretta; A G Siccardi
Journal:  Helv Paediatr Acta       Date:  1979

6.  A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

7.  The properdin system and immunity. V. The bactericidal activity of the properdin system.

Authors:  A C WARDLAW; L PILLEMER
Journal:  J Exp Med       Date:  1956-05-01       Impact factor: 14.307

8.  Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection.

Authors:  R I Lehrer; M J Cline
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

9.  Effect of growth rate and substrate limitation on the composition and structure of the cell wall of Saccharomyces cerevisiae.

Authors:  I McMurrough; A H Rose
Journal:  Biochem J       Date:  1967-10       Impact factor: 3.857

10.  Myeloperoxidase-halide-hydrogen peroxide antibacterial system.

Authors:  S J Klebanoff
Journal:  J Bacteriol       Date:  1968-06       Impact factor: 3.490

View more
  15 in total

1.  Granulocyte-macrophage colony-stimulating factor augments neutrophil killing of Torulopsis glabrata and stimulates neutrophil respiratory burst and degranulation.

Authors:  I C Kowanko; A Ferrante; D P Harvey; K L Carman
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

2.  Deletion of the SSK1 response regulator gene in Candida albicans contributes to enhanced killing by human polymorphonuclear neutrophils.

Authors:  Chen Du; Richard Calderone; John Richert; Dongmei Li
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Enhancement of non-Candida antibody responses by Candida albicans cell wall glycoprotein.

Authors:  J E Domer; K L Elkins; D L Ennist; P W Stashak; R E Garner; P J Baker
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

4.  Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase.

Authors:  Y Aratani; H Koyama; S Nyui; K Suzuki; F Kura; N Maeda
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

5.  Candidacidal activity of myeloperoxidase: therapeutic influence of the enzyme in vivo.

Authors:  C D Wright; R D Nelson
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

6.  Killing of Actinobacillus actinomycetemcomitans by the human neutrophil myeloperoxidase-hydrogen peroxide-chloride system.

Authors:  K T Miyasaki; M E Wilson; R J Genco
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

7.  Relationship between cell surface composition, adherence, and virulence of Candida albicans.

Authors:  J McCourtie; L J Douglas
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  Candida albicans response regulator gene SSK1 regulates a subset of genes whose functions are associated with cell wall biosynthesis and adaptation to oxidative stress.

Authors:  Neeraj Chauhan; Diane Inglis; Elvira Roman; Jesus Pla; Dongmei Li; Jose A Calera; Richard Calderone
Journal:  Eukaryot Cell       Date:  2003-10

9.  Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein.

Authors:  E W Carrow; J E Domer
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

10.  Bactericidal activity against Pseudomonas aeruginosa is acquired by cultured human monocyte-derived macrophages after uptake of myeloperoxidase.

Authors:  M Mathy-Hartert; G Deby-Dupont; P Melin; M Lamy; C Deby
Journal:  Experientia       Date:  1996-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.